机构：[a]Department of Neurology, Xuanwu Hospital, Capital University of Medicine, Beijing 100053, China神经内科[b]Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA[c]Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA[d]Department of Neurosurgery, Xuanwu Hospital, Capital University of Medicine, Beijing 100053, China神经外科[e]Geriatric Research Education and Clinical Centers, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA
Intracranial atherosclerosis (ICAS) is a progressive pathological process that causes progressive stenosis and cerebral hypoperfusion and is a major cause of stroke occurrence and recurrence around the world. Multiple factors contribute to the development of ICAS. Angiography imaging techniques can improve the diagnosis of and the selection of appropriate treatment regimens for ICAS. Neither aggressive medication nor endovascular interventions can eradicate stroke recurrence in patients with ICAS. Non-pharmacological therapies such as remote ischemic conditioning and hypothermia are emerging. Comprehensive therapy with medication in combination with endovascular intervention and/or non-pharmacological treatment may be a potential strategy for ICAS treatment in the future. We summarized the epidemiology, pathophysiological mechanisms, risk factors, biomarkers, imaging and management of ICAS.
第一作者机构：[a]Department of Neurology, Xuanwu Hospital, Capital University of Medicine, Beijing 100053, China
通讯作者：
通讯机构：[b]Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA[d]Department of Neurosurgery, Xuanwu Hospital, Capital University of Medicine, Beijing 100053, China[e]Geriatric Research Education and Clinical Centers, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA
推荐引用方式(GB/T 7714)：
Yuan Wang,Ran Meng,Gang Liu,et al.Intracranial atherosclerotic disease[J].NEUROBIOLOGY OF DISEASE.2019,124:118-132.doi:10.1016/j.nbd.2018.11.008.
